Other Events ·
Metagenomi Therapeutics reports $101.7M cash and FDA clearance for MGX-001 hemophilia A trial
MGXMetagenomi Therapeutics, Inc.
Metagenomi Therapeutics announced the U.S. Food and Drug Administration cleared its Investigational New Drug application for MGX-001, a genome editing treatment for hemophilia A. The company plans to initiate the global Phase 1/2 INTEGR8 clinical trial in the first half of 2027, with initial safety and efficacy data expected in the second half of 2027. For the third quarter ended September 30, 2026, the company reported $101.7 million in cash, cash equivalents, and marketable securities, providing an operating runway into 2028. R&D expenses were $17.5 million, down from $25.3 million in the prior year period. Metagenomi Therapeutics is an in vivo genome editing company developing potentially curative genetic medicines for patients.